CA
NZ
UK
AU
IND
US
• Regencell fell nearly 23% to close at $8.56 on June 24 with no company-specific catalyst identified.
• The company trades with a market capitalisation below $9 million and limited institutional support.
• The stock has gained approximately 282% over the prior twelve months on ophthalmic pipeline optimism.
• The stock has lost approximately 81% over the prior year and 51% year-to-date despite a 63% one-month gain.
• electroCore fell more than 9% on June 24 with no negative regulatory or clinical development identified.
• The stock has lost approximately 99% over the prior twelve months and sits near a 52-week low of around $2.10.
• The stock had surged approximately 176% year-to-date before the session's pullback.
• The stock has lost approximately 46% year-to-date and trades with a market cap of just over $4 million.
• Bluejay fell nearly 23% on June 24, continuing a sharp decline driven by dilutive financing pressure.
• The stock has lost approximately 52% over the prior twelve months and sits near its 52-week low.
Please wait processing your request...